Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Open Access
- 10 February 2022
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 399 (10325), 665-676
- https://doi.org/10.1016/s0140-6736(22)00163-5
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportThe New England Journal of Medicine, 2020
- A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2Nature, 2020
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibodyNature, 2020
- A human monoclonal antibody blocking SARS-CoV-2 infectionNature Communications, 2020
- Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020Eurosurveillance, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsThe New England Journal of Medicine, 2019
- How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?Expert Opinion on Drug Discovery, 2019
- Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human HepatocytesDrug Metabolism and Disposition, 2007
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPEDIATRICS, 1998